Recent failures of highly anticipated drugs show that Big Pharma should "develop a more flexible approach to drug approval and patent exclusivity and change its business model to encourage more scientific collaboration among companies," writes Christopher Bowe, a U.S. health care analyst at Informa Scrip. Working more closely with regulators and payers, accepting sliding patent exclusivity based on comparative effectiveness, and loosening intellectual property protections to encourage more collaboration would help Big Pharma out of the doldrums, Bowe writes.